PaulDMillerMD

PubMed

• 21 citations
  Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
  Ruban Dhaliwal, Didier Hans, Gary Hattersley, Bruce Mitlak, Lorraine A Fitzpatrick, Yamei Wang, Ann V Schwartz, Paul D Miller, Robert G Josse> ;JBMR Plus. 2020 Apr 1
• 3 citations
  Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM an...
  Ethel S. Siris, Michele McDermott, Nicola Pannacciulli, Paul D. Miller, E. Michael Lewiecki, Roland Chapurlat, Esteban Jódar-Gimeno, Shuang Huang, John A. Kanis> ;JBMR Plus. 2020 Feb 24
• 10 citations
  Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis.
  E. Michael Lewiecki, David L. Kendler, K. Shawn Davison, David A. Hanley, Steven T. Harris, Michael R. McClung, Paul D. Miller> ;The American Journal of Medicine. 2019 May 29
• 24 citations
  Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
  John P. Bilezikian, Gary Hattersley, Bruce H. Mitlak, Ming-yi Hu, Lorraine A. Fitzpatrick, C. Dabrowski, Paul D. Miller, Socrates E. Papapoulos> ;Current Medical Research and Opinion. 2019 Sep 11
• 17 citations
  Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.
  Serge Ferrari, Peter W. Butler, David L. Kendler, Paul D. Miller, Christian Roux, A. Wang, Shuang Huang, Rachel B. Wagman, E. Michael Lewiecki> ;The Journal of Clinical Endocrinology and Metabolism. 2019 Aug 1
• Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIV...
  Miller, P. D.,Hattersley, G.,Lau, E.,Fitzpatrick, L. A.,Harris, A. G.,Williams, G. C.,Hu, M. Y.,Riis, B. J.,Russo, L.,Christiansen, C.> ;Bone. 2018 Oct 26
• 27 citations
  Fracture Healing in Two Adult Patients With Hypophosphatasia After Asfotase Alfa Therapy
  Philostratos Klidaras, Jacqueline Severt, Deborah Aggers, Jason E. Payne, Paul D. Miller, Steven W. Ing> ;JBMR Plus. 2018 Sep 1
• Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis.
  Lewiecki, E. M.,Bilezikian, J. P.,Giangregorio, L.,Greenspan, S. L.,Khosla, S.,Kostenuik, P.,Krohn, K.,McClung, M. R.,Miller, P. D.,Pacifici, R.> ;J Clin Densitom. 2018 Oct 28
• To The Editor.
  Miller, P. D.,Bilezikian, J. P.,Lewiecki, E. M.,Watts, N. B.,Carey, J. J.> ;J. Bone Miner. Res.. 2018 Aug 14
• In Memoriam: Michael Kleerekoper: August 18, 1944 to May 10, 2018 In relentless pursuit of a better way.
  Rao, S. D.,Bilezikian, J. P.,Watts, N. B.,Miller, P. D.,McClung, M. R.,Nelson, D. A.> ;J. Bone Miner. Res.. 2018 Jul 17
• 10 citations
  Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.
  Michael R. McClung, Gregory C. Williams, Gary Hattersley, Lorraine A. Fitzpatrick, Yamei Wang, Paul D. Miller> ;Calcified Tissue International. 2018 Jun 1
• A Phase 3 Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
  Lewiecki, E. M.,Blicharski, T.,Goemaere, S.,Lippuner, K.,Meisner, P. D.,Miller, P. D.,Miyauchi, A.,Maddox, J.,Chen, L.,Horlait, S.> ;J. Clin. Endocrinol. Metab.. 2018 Jun 23
• Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
  Michael R. McClung, Gregory C. Williams, Gary Hattersley, Lorraine A. Fitzpatrick, Yamei Wang, Paul D. Miller> ;Calcified Tissue International. 2018 Jun 1
• 101 citations
  ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
  Henry G. Bone, Felicia Cosman, Paul D. Miller, Gregory C. Williams, Gary Hattersley, Ming-yi Hu, Lorraine A. Fitzpatrick, Bruce H. Mitlak, S. Papapoulos, René Rizzoli,...> ;The Journal of Clinical Endocrinology and Metabolism. 2018 Aug 1
• 48 citations
  Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
  David W Dempster, Hua Zhou, Robert R. Recker, Jacques P. Brown, Christopher Recknor, E. Michael Lewiecki, Paul D. Miller, Sudhaker D Rao, David L. Kendler, Robert Lind...> ;Journal of Bone and Mineral Research. 2018 Feb 1
• 12 citations
  Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis
  E. Michael Lewiecki, John P. Bilezikian, John J. Carey, Richard M. Dell, Catherine M. Gordon, Steven T. Harris, Michael R. McClung, Paul D. Miller, Michael Rosenblatt> ;Journal of Clinical Densitometry. 2018 Jan 1
• 1 citations
  Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women.
  Paul D. Miller> ;Annals of Internal Medicine. 2017 Dec 19
• 2 citations
  Bone Density Testing Is the Best Way to Monitor Osteoporosis Treatment.
  Micol S. Rothman, E. Michael Lewiecki, Paul D. Miller> ;The American Journal of Medicine. 2017 Oct 1
• 16 citations
  Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
  David A. Hanley, Michael R. McClung, K. Shawn Davison, Larry Dian, S. T. Harris, Paul D. Miller, E. Michael Lewiecki, David L. Kendler> ;The American Journal of Medicine. 2017 Jul 1
• 9 citations
  The history of bone densitometry.
  Paul D. Miller> ;Bone. 2017 Nov 1
• 43 citations
  Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates
  Nelson B. Watts, Deborah Aggers, Edward F. McCarthy, Tina Savage, Stephanie Martinez, Rachel Patterson, Erin Carrithers, Paul D. Miller> ;Journal of Bone and Mineral Research. 2017 May 1
• 10 citations
  Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases.
  E Michael Lewiecki, John P Bilezikian, Susan V Bukata, Pauline Camacho, Bart L Clarke, Michael R McClung, Paul D Miller, John Shepherd> ;Journal of Clinical Densitometry. 2017 Feb 6
• Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or ...
  Paul D. Miller, Nico Pannacciulli, Rachel B. Wagman, Steven R. Cummings> ;The Journal of Clinical Endocrinology and Metabolism. 2016 Sep 7
• 483 citations
  Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
  Paul D. Miller, Gary Hattersley, Bente Juel Riis, Gregory C. Williams, Edith M. C. Lau, Luis A. Russo, Peter Alexandersen, Cristiano Augusto de Freitas Zerbini, Ming-y...> ;JAMA. 2016 Aug 16
• 33 citations
  A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zol...
  David W. Dempster, Hua Zhou, Robert R. Recker, Jacques P. Brown, Michael A. Bolognese, Christopher Recknor, David L. Kendler, E. Michael Lewiecki, David A. Hanley, Sud...> ;Journal of Bone and Mineral Research. 2016 Jul 1
• Join now to see all